Min Ni received her Ph.D. from the University of Southern California (USC) at Los Angeles, where she studied the endoplasmic reticulum stress response in cancers with Dr. Amy Lee at the USC Norris Comprehensive Cancer Center. In 2008, she started her postdoctoral training with Dr. Myles Brown at Dana-Farber Cancer Institute and Harvard Medical School, studying the function of androgens in breast cancer funded by her scholarship from the U.S. Department of Defense. In 2011, she became an Instructor in medical oncology at Harvard Medical School. Dr. Ni joined Infinity Pharmaceuticals in Boston in 2013 where she worked on clinical trials testing new therapeutics for leukemia and lymphoma. In 2014, she joined the Genetic and Metabolic Disease Program at the Children’s Medical Research Institute at UT Southwestern as an assistant professor.

Dr. Ni's research focuses on discovering disease-causing genes in patients with undiagnosed genetic disorders and understanding the physiological impact of known but inadequately treated metabolic diseases. 

Research Summary


Wuhan University (2000), Biology
Graduate School
Fudan University (2003), Oncology
Graduate School
University of Southern Califor (2008), Biochemistry

Research Interest

  • Functional genomics, metabolomics and bioinformatics
  • Genetic and metabolic diseases
  • Translational Research


Featured Publications LegendFeatured Publications

Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers.
Huang F, Ni M, Chalishazar MD, Huffman KE, Kim J, Cai L, Shi X, Cai F, Zacharias LG, Ireland AS, Li K, Gu W, Kaushik AK, Liu X, Gazdar AF, Oliver TG, Minna JD, Hu Z, DeBerardinis RJ Cell Metab. 2018 Jun
Lactate Metabolism in Human Lung Tumors.
Faubert B, Li KY, Cai L, Hensley CT, Kim J, Zacharias LG, Yang C, Do QN, Doucette S, Burguete D, Li H, Huet G, Yuan Q, Wigal T, Butt Y, Ni M, Torrealba J, Oliver D, Lenkinski RE, Malloy CR, Wachsmann JW, Young JD, Kernstine K, DeBerardinis RJ Cell 2017 Oct 171 2 358-371.e9
In Situ Capture of Chromatin Interactions by Biotinylated dCas9.
Liu X, Zhang Y, Chen Y, Li M, Zhou F, Li K, Cao H, Ni M, Liu Y, Gu Z, Dickerson KE, Xie S, Hon GC, Xuan Z, Zhang MQ, Shao Z, Xu J Cell 2017 Aug 170 5 1028-1043.e19
Metabolic Heterogeneity in Human Lung Tumors.
Hensley CT, Faubert B, Yuan Q, Lev-Cohain N, Jin E, Kim J, Jiang L, Ko B, Skelton R, Loudat L, Wodzak M, Klimko C, McMillan E, Butt Y, Ni M, Oliver D, Torrealba J, Malloy CR, Kernstine K, Lenkinski RE, DeBerardinis RJ Cell 2016 Feb 164 4 681-94
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, Peluffo G, Brown J, D'Santos C, Krop IE, Dillon D, McKeown M, Ott C, Qi J, Ni M, Rao PK, Duarte M, Wu SY, Chiang CM, Anders L, Young RA, Winer EP, Letai A, Barry WT, Carroll JS, Long HW, Brown M, Liu XS, Meyer CA, Bradner JE, Polyak K Nature 2016 Jan 529 7586 413-7
Importance of Breast Cancer Subtype in the Development of Androgen Receptor Directed Therapy.
Lim E, Ni M, Cao S, Hazra A, Tamimi RM, Brown M Curr Breast Cancer Rep 2014 Jun 6 2 71-78

Honors & Awards

  • Award for Genetics and Genomics of Breast and Gyn Cancers, Harvard Cancer Center (2013)

Professional Associations/Affiliations

  • Endocrine Society (2010)
  • American Association for Cancer Research (2007)